Centene ($CNC) Revenue Guidance Collapse and Misleading Marketplace Metrics Case

Court: S.D. New York

Case: 1:25-cv-05659

• CNC investors filed a claim against Centene for misleading the market about its 2025 earnings outlook, falsely inflating enrollment and morbidity assumptions across its health insurance marketplace business, and issuing overly optimistic guidance unsupported by internal data.
• On July 1, 2025, Centene abruptly withdrew its full-year guidance, revealing a $1.8 billion risk adjustment. CNC plummeted 40.4% in one day.
• CNC investors can join this case to be notified about potential recovery.

Case Details:

From December 12, 2024, to June 30, 2025, Centene repeatedly reaffirmed and raised its 2025 revenue and EPS guidance, claiming strong Medicare enrollment, stable morbidity, and robust marketplace growth. Executives told investors the company was outperforming expectations and positioned for durable earnings.

In reality, Centene’s internal analysis showed early signs of lower marketplace growth and higher-than-expected morbidity in its core states, contradicting public statements. Defendants concealed this risk and continued to project >$7.25 in 2025 EPS until the last minute.

On July 1, 2025, Centene disclosed that 2025 marketplace risk adjustment revenue would fall short by ~$1.8 billion across 22 states, or 72% of its marketplace membership, with further downside likely from the remaining states. The company withdrew guidance and warned of future repricing efforts for 2026.

Analysts called the update a "tough reset" and slashed price targets. Guggenheim estimated actual 2025 EPS closer to $2.50–$3.00, less than half prior guidance. CFRA flagged a “disconnect” in Centene’s modeling. Barclays warned the announcement signaled early signs of ACA marketplace instability.

Based on these revelations, investors allege that Centene:

• It misrepresented enrollment strength and market stability to justify inflated 2025 projections.
• It withheld material data about higher morbidity and lower marketplace growth uncovered in internal reviews.

Investors believe Centene issued false and misleading guidance that materially misrepresented its 2025 outlook and marketplace fundamentals.